- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: GA-101 | GA101 | Gazyva®
obinutuzumab is an approved drug (FDA (2013), EMA (2014))
Compound class: Antibody
Comment: Obinutuzumab is a third-generation, humanized and glyco-engineered anti-CD20 IgG1 mAb. Prior to 2009 obinutuzumab was known as afutuzumab.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
View more information in the IUPHAR Pharmacology Education Project: obinutuzumab
|Chronic lymphocytic leukemia||
|Approved for use in combination with chemotherapy in patients who have received no prior therapy.|
||Approval is for a combination therapy of obinutuzumab with bendamustine, followed by obinutuzumab monotherapy.|